08 Feb, 2023
Evaxion and Pantherna announce promising preclinical mRNA vaccine data
COPENHAGEN, Denmark and HENNIGSDORF, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies and Pantherna Therapeutics GmbH (“Pantherna”), a biopharmaceutical company developing advanced nanoparticle solutions for the delivery and expression of mRNA therapeutics, today announced preclinical proof of concept for the combination of the two companies’ key technologies.
The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model when delivered using Pantherna’s proprietary lipid nanoparticle mRNA platform (PTXΔLNP®, PTXmRNA®).
“We are extremely pleased with the preclinical data that clearly demonstrate the potential for our combined technologies. The data provide further evidence that immunogenic sequences identified by Evaxion’s AI platforms are able to drive a relevant immune response on multiple vaccine platforms, including mRNA. This opens up many opportunities in our current and future immuno-oncology and infectious disease programs,” says Birgitte Rønø, CSO at Evaxion.
“We are encouraged by the data and see an enormous potential of combining Evaxion’s AI-based antigen discovery engines with our state-of-the-art mRNA-LNP platforms. The preclinical data substantiate the relevance of enhancing the efficiency of mRNA actions in the body and validates the ability of our platform to induce an immune response,” says Klaus Giese, CEO at Pantherna.
In continuation of these positive findings, Evaxion and Pantherna will further explore optimal LNP formulations to effectively deliver mRNA and DNA-encoded antigens identified by Evaxion’s AI platforms.
Evaxion Biotech A/S is a clinical-stage biotech company developing AI-powered immunotherapies. Evaxion’s proprietary and scalable AI technologies decode the human immune system to discover and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of novel product candidates, including three personalized cancer immunotherapies. It is located in Hørsholm, Denmark, with 70 employees and is listed on the Nasdaq New York stock exchange. For more information, please visit: www.evaxion-biotech.com.
Pantherna Therapeutics is a privately held biopharmaceutical company developing first-in-class mRNA therapeutics. Pantherna’s innovative technology platform is based on advanced lipid nanoparticles for the target-specific, selective delivery and expression of therapeutic mRNA drugs in organs and tissues such as the vascular endothelium. Pantherna is based in Hennigsdorf, Brandenburg (Innovationsforum) close to Berlin, Germany. For more information, please visit https://pantherna-therapeutics.com/.
For more information, please contact:
Katrine Hertz Mortensen
VP, Communications and Public Relations
+45 3010 0203
+49 3302-202 240-0
FULL TEXT (EN)